A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor

• Päätekijät: Qi Zhang (Tekijä), Ting Deng (Tekijä), Fen Yang (Tekijä), Weijian Guo (Tekijä), Dan Liu (Tekijä), Jiajia Yuan (Tekijä), Changsong Qi (Tekijä), Yanshuo Cao (Tekijä), Qiuqiong Yu (Tekijä), Huiming Cai (Tekijä), Zhi Peng (Tekijä), Xicheng Wang (Tekijä), Jun Zhou (Tekijä), Ming Lu (Tekijä), Jifang Gong (Tekijä), Jian Li (Tekijä), Yi Ba (Tekijä), Lin Shen (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Simmitecan is a potent inhibitor of topoisomerase I with anti-tumor activity. This phase Ib trial was conducted to investigate the safety and anti-tumor effect of simmitecan alone or in combination with other drugs.Methods: Eligible patients with advanced solid tumor had no further stand...